View Older Stories View More Recent Stories
-
Lyra Therapeutics Completes $30 Million Series C Financing
-
Quench Bio Closes $50M Series A Financing to Advance First-in-Class Medicines Targeting Gasdermin to Treat Severe Inflammatory Diseases
-
Iterum Therapeutics (ITRM) Announces $52 Million Private Placement
-
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
-
Iterum Therapeutics Announces $52 Million Private Placement with New and Existing Investors
-
Tyra Biosciences raises $50M to develop therapies targeting acquired resistance in oncology
-
Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference
-
Cerebral Therapeutics Completes $35 Million Series B Financing
-
Vor Biopharma Expands Leadership Team with Chief Legal Officer and Vice President of People
-
FORMA Therapeutics Announces Closing of $100 Million Series D Financing
-
Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development
-
Black Diamond Therapeutics Closes $85 Million Series C Financing
-
Vor Biopharma and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Hematopoietic Stem Cells (eHSCs) to Treat Cancer
-
Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Sep 30
-
Form SC 13D 89bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Chemical & Engineering News Names Frontier Medicines One of its 10 Chemistry Start-Ups to Watch
-
Form SC 13G Phathom Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
X4 Pharmaceuticals Appoints Derek Meisner, J.D., as General Counsel
-
PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
-
Form SC 13G/A RHYTHM PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13D/A Ra Pharmaceuticals, Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Ivantis Completes Enrollment of International SPECTRUM Registry for Hydrus Microstent
-
Vor Biopharma Hires Senior Cell and Gene Therapy Leaders as Chief Technology Officer and Vice President of Research
-
Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019
-
FierceBiotech names Frontier Medicines one of its "Fierce 15" biotech companies of 2019
-
Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer
-
Form SC 13D Satsuma Pharmaceuticals, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Nkarta Therapeutics Appoints Vice President of Regulatory Affairs
-
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs into Clinical Trials
-
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
-
Achilles Therapeutics raises £100 million in oversubscribed Series B financing
-
ESSA Pharma Completes Public Offering and Concurrent Private Placement for Aggregate Gross Proceeds of US$36 Million
-
ESSA Pharma Inc. (EPIX) Anounces Proposed $36M Share Offering and Concurrent Private Placement
-
ESSA Pharma Announces $36 Million Public Offering of Common Stock and Concurrent Private Placement
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Solid Biosciences (SLDB) Tops Q2 EPS by 3c
-
Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update
-
Vor Biopharma Appoints Veteran Biotech Executive Dr. Robert Ang as President and Chief Executive Officer
-
Frontier Medicines Announces Three Executive Hires: Chief Scientific Officer, Chief Technology Officer & Head of Degrader Technologies
-
Vor Biopharma Appoints Dr. Bill Lundberg to Its Board of Directors
-
Form SC 13D/A Solid Biosciences Inc. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Solid Biosciences (SLDB) Announces $60 Million Private Placement of Common Stock and Warrants
-
Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
-
Freenome Closes $160 Million Series B Financing to Advance Its Multiomics Blood Testing Platform for Early Cancer Detection
-
RA Capital Management Closes First Venture Fund
-
Form SC 13G/A InflaRx N.V. Filed by: RA CAPITAL MANAGEMENT, LLC
-
Frontier Medicines launches with $67 million to develop novel medicines that drug the "undruggable" targets driving human disease
-
Phathom Pharmaceuticals to Present at Jefferies 2019 Healthcare Conference
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Mar 31

